GlaxoSmithKline Pakistan Limited (PSX:GLAXO)

Pakistan flag Pakistan · Delayed Price · Currency is PKR
413.42
-2.15 (-0.52%)
At close: Feb 13, 2026
Market Cap131.66B -0.8%
Revenue (ttm)62.07B +10.4%
Net Income9.19B +103.9%
EPS28.85 +103.9%
Shares Out318.47M
PE Ratio14.33
Forward PE12.62
Dividend10.00 (2.42%)
Ex-Dividend DateSep 5, 2025
Volume178,430
Average Volume238,903
Open415.57
Previous Close415.57
Day's Range411.00 - 419.00
52-Week Range301.00 - 481.00
Beta0.35
RSI44.80
Earnings DateMar 4, 2026

About GlaxoSmithKline Pakistan

GlaxoSmithKline Pakistan Limited operates as a biopharma company in Pakistan. It deals in anti-infective, dermatology, respiratory, immunology, oncology, infectious diseases, HIV, and vaccines therapy areas. The company sells its products under the Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol, and Cutivate brands. It also exports its products. The company was founded in 2001 and is headquartered in Karachi, Pakistan. GlaxoSmithKline Pakistan Limited is a subsidiary of GSK plc. [Read more]

Industry Pharmaceuticals
Sector Healthcare
Founded 2001
Employees 1,700
Stock Exchange Pakistan Stock Exchange
Ticker Symbol GLAXO
Full Company Profile

Financial Performance

In 2024, GlaxoSmithKline Pakistan's revenue was 61.19 billion, an increase of 23.21% compared to the previous year's 49.66 billion. Earnings were 6.54 billion, an increase of 1124.09%.

Financial Statements